First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials
Giuseppe Cabibbo(University of Palermo), Calogero Cammà(University of Palermo), Ferràn Torres(Evidence (Italy)), Vincenza Calvaruso(University of Palermo), Ciro Celsa(Hammersmith Hospital), V. Di Marco(University of Palermo), Giacomo Emanuele Maria Rizzo(University of Palermo), Salvatore Battaglia(University of Palermo), Salvatore Petta(Department of Health), Jordi Bruix(Universitat de Barcelona), María Reig(Universitat de Barcelona), Marco Enea(University of Palermo), Antonio Craxı̀(University of Palermo), Amit G. Singal(The University of Texas Southwestern Medical Center)
Cited by 50
Related Papers
Management of Hepatocellular Carcinoma: An Update Δσ
|Hepatology|2011|8.1k
Management of Hepatocellular Carcinoma *
|Hepatology|2005|5.9k
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
|Journal of Hepatology|2001|4.1k
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
|Gastroenterology|2016|1.8k
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
|JNCI Journal of the National Cancer Institute|2008|1.7k